Targeting epigenetic regulators for cancer therapy

Susan Wee, Dash Dhanak, Haitao Li, Scott A. Armstrong, Robert A. Copeland, Robert J. Sims, Stephen B. Baylin, Xiaole Shirley Liu, Liang SchweizerAnnals 2014 · DOI

TL;DR

This paper reviews the exciting advancements in targeting epigenetic regulators for cancer therapy. It highlights how understanding the "epigenetic code" and developing small-molecule inhibitors for key regulators like DOT1L and EZH2 are leading to promising new treatments for various leukemias and other cancers, with some already in clinical trials.

What Problem Does This Paper Address?

Cancer is a complex disease driven by both genetic mutations and epigenetic alterations. While genetic mutations have long been a focus of cancer research and therapy, the role of epigenetics – changes in gene expression that don't involve alterations to the underlying DNA sequence – is increasingly recognized as crucial. Epigenetic dysregulation can lead to widespread changes in gene expression, contributing to cancer development and progression. The challenge lies in identifying specific epigenetic regulators that are aberrantly active in cancer cells and developing targeted therapies to counteract these changes, offering a new avenue for treatment, especially for cancers with limited therapeutic options.

Methods

The paper is a review and summary of a symposium, so it doesn't present novel experimental methods. Instead, it discusses the application of various research methodologies:

  • Genomic and Epigenomic Studies: Next-generation sequencing (NGS) and chromatin immunoprecipitation followed by sequencing (ChIP-seq) are used to map epigenetic modifications and identify regulatory elements.
  • Biochemical Assays: These are used to characterize the activity of epigenetic enzymes and the binding of reader proteins to histone modifications.
  • Preclinical Models: Cell culture studies and xenograft animal models are employed to test the efficacy of small-molecule inhibitors.
  • Clinical Trials: The paper discusses the progression of promising drug candidates into human clinical trials.
  • Structural Biology: High-resolution structures of epigenetic regulators are being pursued to aid in rational drug design.

Datasets

Not discussed in the paper. The paper focuses on summarizing research findings and clinical progress rather than presenting new data from specific datasets.

Key Insights and Ideas

  • The "Epigenetic Code" is Complex and Combinatorial: It's not just about single histone modifications but rather patterns and combinations of marks that are read by specific protein modules. This complexity offers both challenges and opportunities for targeted therapy.
  • Epigenetic Regulators as Druggable Targets: Key epigenetic enzymes like DOT1L (involved in H3K79 methylation) and EZH2 (involved in H3K27 methylation) are crucial for the survival and proliferation of certain cancer types, making them excellent targets for small-molecule inhibitors.
  • MLL-Rearranged Leukemias are Highly Dependent on DOT1L: This specific type of leukemia is driven by MLL gene rearrangements, and its leukemogenic activity is significantly reliant on DOT1L's function. Inhibiting DOT1L shows strong therapeutic potential.
  • EZH2 Mutations in Cancer Can Lead to Aberrant Activity: While initially thought to be loss-of-function, some EZH2 mutations can alter its substrate specificity, contributing to hyperproliferation in cancers like non-Hodgkin lymphoma.
  • BET Family Proteins are Key Regulators of MYC: Inhibitors targeting BET bromodomains can rapidly abrogate MYC transcription, leading to growth arrest and apoptosis in MYC-dependent cancers.
  • Epigenetic Therapy Offers a New Paradigm: Beyond directly killing cancer cells, epigenetic therapies can also sensitize tumors to chemotherapy and immunotherapy, or even influence cell differentiation pathways.

Key Results

  • DOT1L Inhibitors (e.g., EPZ-5676): Showed potent inhibition of DOT1L activity and significant tumor growth inhibition, leading to complete eradication in MLL-rearranged leukemia models. EPZ-5676 has advanced to Phase 1 clinical trials.
  • EZH2 Inhibitors (e.g., EPZ-6438): Demonstrated selective killing of EZH2-mutant cancer cells and significant tumor growth inhibition in preclinical models of malignant rhabdoid tumors. EPZ-6438 is expected to enter Phase 1 clinical testing.
  • BET Inhibitors (e.g., CPI-BETi, CPI-0610): Showed potent abrogation of MYC transcription, leading to tumor regression in preclinical models and initiating clinical trials for lymphomas.

Limitations and Future Work

  • Understanding Off-Target Effects: While inhibitors are becoming more selective, a deeper understanding of potential liabilities and off-target effects is crucial for patient safety and efficacy.
  • Combinatorial Therapies: The paper suggests that combining epigenetic therapies with other treatment modalities (chemotherapy, immunotherapy, differentiation therapy) holds significant promise.
  • Biomarkers for Response: Developing reliable biomarkers to predict patient response to epigenetic therapies is essential for effective patient stratification in clinical trials.
  • Broader Roles of Epigenetic Regulators: Research is expanding beyond direct chromatin regulation to explore other cellular functions of epigenetic targets, which could reveal new therapeutic avenues.
  • Optimizing Dosing and Scheduling: For existing hypomethylating agents, optimizing dosing and scheduling is being explored for improved efficacy and tolerability in solid tumors.

Summary updated

Abstract

Human gene expression patterns are controlled and coordinated by the activity of a diverse array of epigenetic regulators, including histone methyltransferases, acetyltransferases, and chromatin remodelers. Deregulation of these epigenetic pathways can lead to genome-wide changes in gene expression, with serious disease consequences. In recent years, research has suggested that cross talk between genomic (i.e., for example, mutations, translocations) and epigenomic factors may drive the etiology of both hematologic malignancies and solid tumors. Current work in translational research seeks to identify epigenetic regulators whose aberrant activity contributes to oncogenesis, including the histone methyltransferases DOT1L and EZH2 and the bromodomain-containing BET family, and to develop drugs that inhibit the aberrant activity of these regulators. Preclinical and clinical studies using small-molecule inhibitors of epigenetic regulators have underscored their value for therapeutic intervention, and these inhibitors can also be used to drive further studies into dissecting the functions of epigenetic factors in normal and cancer cells.
BibTeX
@article{wee2014targeting,
  author = {Susan Wee and Dash Dhanak and Haitao Li and Scott A. Armstrong and Robert A. Copeland and Robert J. Sims and Stephen B. Baylin and Xiaole Shirley Liu and Liang Schweizer},
  title = {{Targeting epigenetic regulators for cancer therapy}},
  journal = {Annals},
  year = {2014},
  doi = {10.1111/nyas.12356},
}
Figure